CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC

Opinion
Video

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Recent Videos
Related Content
Sacituzumab Govitecan Delivers Rapid Responses in Cisplatin-Ineligible Bladder Cancer

Sacituzumab Govitecan Delivers Rapid Responses in Cisplatin-Ineligible Bladder Cancer

Sabrina Serani
October 1st 2024
Article

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with locally advanced or metastatic urothelial carcinoma.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

High-Sensitivity ctDNA Marks the Next Frontier in Genitourinary Oncology

High-Sensitivity ctDNA Marks the Next Frontier in Genitourinary Oncology

Jordyn Sava
September 26th 2024
Article

Arnab Basu, MD, MPH, FACP, discussed his research on high-sensitivity circulating tumor DNA assays in genitourinary malignancies.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads to Improved HRQOL, Tolerability in mCRPC

Tony Berberabe, MPH
September 16th 2024
Article

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Read More

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Radium-223 Enhances Outcomes with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Megan Hollasch
September 15th 2024
Article

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

Read More